Stemming the tide of hepatitis B virus-related hepatocellular carcinoma?

Journal of Clinical Oncology

Volumn 26, Issue 2, 2008, Pages 172-174

  Thomas, Melanie B ^a   Davila, Marta ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; VIRUS DNA;

EDITORIAL; GENE MUTATION; GENOTYPE; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MORBIDITY; MORTALITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; CARCINOMA, HEPATOCELLULAR; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; POPULATION SURVEILLANCE; RISK FACTORS; VIRAL LOAD;

EID: 38549106055     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.4337     Document Type: Editorial

References (59)

1. Lavanchy D: Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34:S1-S3, 2005 (suppl)
2. Goldstein ST, Zhou F, Hadler SC, et al: A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34:1329-1339, 2005
3. Merican I, Guan R, Amarapuka D, et al: Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 15:1356-1361, 2000
4. Simonetti RG, Camma C, Fiorello F, et al: Hepatocellular carcinoma: A worldwide problem and the major risk factors. Dig Dis Sci 36:962-972, 1991
5. Popper H: Relation between hepatocellular carcinoma and persistent hepatitis B infection. Appl Pathol 6:64-72, 1988
6. Leung N: HBV and liver cancer. Med J Malaysia 60:63-66, 2005 (suppl)
7. Michielsen PP, Francque SM, van Dongen JL: Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol 3:27, 2005
8. Sylla A, Diallo MS, Castegnaro J, et al: Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma: A molecular epidemiological approach. Mutat Res 428:187-196, 1999
9. Kao JH, Chen DS: Global control of hepatitis B virus infection. Lancet Infect Dis 2:395-403, 2002
10. Madani TA: Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia. Trans R Soc Trop Med Hyg 101:278-283, 2007
11. Yao JL: Perinatal transmission of hepatitis B virus infection and vaccination in China. Gut 38:S37-S38, 1996 (suppl)
12. Zanetti A: Hepatitis B vaccination: An important method of preventing HBV-related hepatocellular carcinoma. Ital J Gastroenterol 24:100-102, 1992
13. Tron F: Hepatitis B vaccine: Clinical experience. IARC Sci Publ 279-295, 1984
14. van der Sande MA, Mendy M, Waight P, et al: Similar long-term vaccine efficacy of two versus three doses of HBV vaccine in early life. Vaccine 25:1509-1512, 2007
15. Merican I: Screening for hepatocellular carcinoma. Med J Malaysia 51:12-17, 1996
16. Oda T: Viral hepatitis and hepatocellular carcinoma prevention strategy in Japan. Jpn J Cancer Res 90:1051-1060, 1999
17. Hanazaki K: Antiviral therapy for chronic hepatitis B: A review. Curr Drug Targets Inflamm Allergy 3:63-70, 2004
18. Heller S, Valencia-Mayoral P: Treatment of viral hepatitis in children. Arch Med Res 38:702-710, 2007
19. Wright TL: Antiviral therapy and primary and secondary prevention of hepatocellular carcinoma. Hepatol Res 37:S294-S298, 2007 (suppl)
20. Lin SM, Sheen IS, Chien RN, et al: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971-975, 1999
21. Lin SM, Yu ML, Lee CM, et al: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46:45-52, 2007
22. Liu Q, Song Y, Zhou Y, et al: A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther 5:1674-1676, 2006
23. Lok AS, Ma OC, Lau JY: Interferon alfa therapy in patients with chronic hepatitis B virus infection: Effects on hepatitis B virus DNA in the liver. Gastroenterology 100:756-761, 1991
24. Hino O: Intentional delay of human hepatocarcinogenesis due to suppression of chronic hepatitis. Intervirology 48:6-9, 2005
25. Wild CP, Hall AJ: Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 462:381-393, 2000
26. Sung JL: Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 12:S370-S376, 1997
27. Liaw YF: Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 25:40-47, 2005 (suppl)
28. Lodato F, Mazzella G, Festi D, et al: Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 12:7239-7249, 2006
29. Stuver SO: Towards global control of liver cancer? Semin Cancer Biol 8:299-306, 1998
30. Wong ET, Chew YP, Lee LA, et al: Therapeutic strategies for hepatitis B virus-associated hepatocellular carcinoma. Curr Drug Targets 3:369-378, 2002
31. Lok AS: Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology 127:S303-S309, 2004
32. Velu V, Nandakumar S, Shanmugam S, et al: Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India. World J Gastroenterol 13:3084-3089, 2007
33. Kim SY, Billah K, Lieu TA, et al: Cost effectiveness of hepatitis B vaccination at HIV counseling and testing sites. Am J Prev Med 30:498-506, 2006
34. Vimolket T, Poovorawan Y: An economic evaluation of universal infant vaccination strategies against hepatitis B in Thailand: An analytic decision approach to cost-effectiveness. Southeast Asian J Trop Med Public Health 36:693-699, 2005
35. Boyles S: Is universal better than selective immunization in developing world? Vaccines (HBV). Hepatitis Weekly 7-8, October 19, 1998
36. Ho NK: Perinatal infections: Problems in developing countries. Singapore Med J 39:266-270, 1998
37. Krahn M, Detsky AS: Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Med Decis Making 13:4-20, 1993
38. Guidozzi F, Schoub BD, Johnson S, et al: Should pregnant urban south African women be screened for hepatitis B? S Afr Med J 83:103-105, 1993
39. Okamoto H, Tsuda F, Sakugawa H, et al: Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes. J Gen Virol 69:2575-2583, 1988
40. Alestig E, Hannoun C, Horal P, et al: Hepatitis B virus genotypes in Mongols and Australian Aborigines. Arch Virol 146:2321-2329, 2001
41. Lindh M, Hannoun C, Dhillon AP, et al: Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis 179:775-782, 1999
42. Orito E, Ichida T, Sakugawa H, et al: Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001
43. Shiina S, Fujino H, Kawabe T, et al: Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease: Part II, Evaluation of epidemiological factors and suspected risk factors of liver dysfunction. Am J Gastroenterol 86:872-875, 1991
44. Shiina S, Fujino H, Uta Y, et al: Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease: Part I, Analysis of 1744 HBsAg carriers. Am J Gastroenterol 86:866-871, 1991
45. Chan HL, Tsang SW, Liew CT, et al: Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 97:406-412, 2002
46. Kao JH, Chen PJ, Lai MY, et al: Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 40:1207-1209, 2002
47. Kao JH, Chen PJ, Lai MY, et al: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559, 2000
48. Sumi H, Yokosuka O, Seki N, et al: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37:19-26, 2003
49. Chan HL, Hui AY, Wong ML, et al: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 53:1494-1498, 2004
50. Yu MW, Yeh SH, Chen PJ, et al: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 97:265-272, 2005
51. Kao JH, Chen PJ, Lai MY, et al: Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334, 2003
52. Liu CJ, Chen BF, Chen PJ, et al: Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis 193:1258-1265, 2006
53. Tanaka Y, Mukaide M, Orito E, et al: Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol 45:646-653, 2006
54. Yuen MF, Tanaka Y, Shinkai N, et al: Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/ C, specific mutations of enhancer II/ core promoter/ precore regions and HBV DNA levels. Gut [Epub ahead of print, May 4, 2007]
55. Yuan J, Zhou B, Tanaka Y, et al: Hepatitis B virus (HBV) genotypes/ subgenotypes in China: Mutations in core promoter and precore/core and their clinical implications. J Clin Virol 39:87-93, 2007
56. Chan HLK, Tse CH, Mo F, et al: High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 26:177-182, 2008
57. Coffin CS, Lee SS: Chronic hepatitis B: Who should be treated? Med Gen Med 8:75, 2006
58. Sherman M: Optimizing management strategies in special patient populations. Am J Gastroenterol 101:S26-S31, 2006 (suppl)
59. Nguyen MH, Keeffe EB: Screening for hepatocellular carcinoma. J Clin Gastroenterol 35:S86-S91, 2002